Infanrix Polio

Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin, the active ingredient in Infanrix Polio, is a vaccine presented as an injectable suspension for intramuscular use. It is used to prevent poliomyelitis type 3 and pertussis in infants and children.

GNH USA supplies Infanrix Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix Polio is a combination vaccine that targets viral and bacterial agents responsible for serious childhood diseases. - Poliomyelitis (type 3): induces protective immunity against poliovirus type 3. - Pertussis (whooping cough): stimulates antibodies against pertussis filamentous haemagglutinin. - Infants and young children: contributes to the recommended early‑childhood immunisation schedule.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site. - Redness or swelling: localized erythema that resolves within a few days. - Low‑grade fever: transient rise in body temperature. - Irritability or fussiness: especially in younger children. - Decreased appetite: temporary reduction in food intake. - Headache: mild headache reported by some recipients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: febrile or non‑febrile convulsions. - High fever: temperature > 40 °C persisting beyond 24 hours. - Hypotonic hyporesponsive episode: marked limpness and reduced responsiveness. - Encephalopathy: rare inflammation of the brain. - Guillain‑Barré syndrome: extremely rare peripheral neuropathy.

Infanrix Polio should be administered with consideration of the following precautions. - Allergy assessment: avoid in individuals with known hypersensitivity to any vaccine component. - Immunocompromised patients: consult a healthcare provider before vaccination. - Acute illness: postpone if the child has moderate or severe fever or illness. - Previous severe reaction: monitor closely after a prior dose that caused a serious local reaction. - Pregnancy: safety not established; use only if the benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by other medical products. Major Interactions (Avoid): - Live attenuated vaccines: do not co‑administer within 4 weeks. - Immunoglobulin therapy: may diminish immune response if given within 2 weeks before or after vaccination. Moderate Interactions (Monitor Closely): - Antipyretics: can be used for fever but may blunt antibody response if taken prophylactically. - High‑dose corticosteroids: may reduce vaccine efficacy. - Blood products: transfusion within 48 hours could affect immune response.